AbbVie Announces Topline Results From Its Phase 3 LUNA Study Of Atogepant For Preventive Treatment Of Menstrual Migraine In Adults; Atogepant Demonstrated Statistically Significant Reductions In Migraine Days Associated With Menstrual Period, Meeting Primary And All Eight Ranked Secondary Endpoints Versus Placebo
These results reinforce AbbVie's scientific expertise in migraine and its focus on advancing solutions for people living with complex and disabling migraine attacks."These positive Phase 3 LUNA results represent
AbbVie's new migraine medicine passed a big test by helping people with period-related migraines feel better than a fake pill. When a company proves its medicine works, it often means good news for the stock and patients who need that help.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.